Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations

Ricardo Caballero1, Ricardo Gómez, Lucía Núñez

  • 1Department of Pharmacology, School of Medicine, Universidad Complutense, 28040 Madrid, Spain. rcaballero@ift.csic.es

Cardiovascular Research
|November 13, 2004
PubMed

Insights

Diltiazem, a common arrhythmia drug, blocks cardiac potassium channels hKv1.5 and Kv4.3. This study reveals diltiazem binds to open and inactivated states of these channels, impacting cardiac electrical activity.

Area of Science:

  • Cardiovascular Pharmacology
  • Ion Channel Physiology
  • Cardiac Electrophysiology

Background:

  • Diltiazem is a widely used L-type Ca(2+) channel blocker for supraventricular arrhythmias.
  • Cardiac potassium channels, including hKv1.5 (I(Kur)) and Kv4.3 (I(to)), are crucial for cardiac action potential repolarization.

Purpose of the Study:

  • To investigate the effects of diltiazem on human Kv1.5 (hKv1.5) and Kv4.3 potassium channels.
  • To determine the mechanism of diltiazem's interaction with these specific cardiac ion channels.

Main Methods:

  • Stable and transient expression of hKv1.5 and Kv4.3 channels in mammalian cell lines.
  • Whole-cell patch-clamp electrophysiology to record potassium currents.
  • Dose-response, frequency-dependent, and voltage-dependence analyses of channel block.

Main Results:

  • Diltiazem exhibited frequency-dependent block of both hKv1.5 and Kv4.3 channels with biphasic dose-response curves.
  • Blockade of hKv1.5 channels involved shifts in activation and inactivation curves.
  • Diltiazem accelerated inactivation of Kv4.3 channels and shifted its inactivation voltage-dependence.

Conclusions:

  • Diltiazem effectively reduces hKv1.5 and Kv4.3 currents.
  • The drug binds to both open and inactivated states of hKv1.5 and Kv4.3 channels.
  • These findings provide novel insights into diltiazem's electrophysiological effects at the channel level.
Abstract

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...